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Recent human genetic studies and postmortem brain examinations of schizophrenia patients strongly indicate that dysregulation
of NRG1 and ErbB4 may be important pathogenic factors of schizophrenia. However, this hypothesis has not been validated
and fully investigated in animal models of schizophrenia. In this study we quantitatively examined NRG1 and ErbB4 protein
expressions by immunohistochemistry and Western blot in the brain of a rat schizophrenia model induced by chronic
administration of MK-801 (a noncompetitive NMDA receptor antagonist). Our data showed that NRG1β and ErbB4 expressions
were signiﬁcantly increased in the rat prefrontal cortex and hippocampus but in diﬀerent subregions. These ﬁndings suggest that
altered expressions of NRG1 and ErbB4 might be attributed to the schizophrenia. Further study in the role and mechanism of
NRG1 and ErbB4 may lead to better understanding of the pathophysiology for this disorder.
1.Introduction
Schizophrenia is a complex and severe brain disorder with
poorly deﬁned etiology and pathophysiology. Emerging
clinical investigations have suggested that there are certain
susceptible genes that may be responsible of the pathophysi-
ology of schizophrenia, such as COMT (Catechol-O-methyl
transferase), DTNBP1 (Dysbindin), NRG1 (Neuregulin 1),
ErbB4, RGS4 (Regulator of G-protein signaling 4), DISC1
(Disrupted-in-schizophrenia 1), and G72 [1–5]. NRG1 and
ErbB4 transgenic mice have shown “schizophrenia-like”
behavioral deﬁcits, indicating that NRG1 and its receptor
ErbB4 might be two of crucial pathogenic factors for the
schizophrenia [6–8].
Accumulating reports have demonstrated the signiﬁ-
cance of NRG1 and ErbB4 function in the brain. For
example, NRG1 comprises a family of transmembrane
or secreted proteins, sharing an epidermal growth factor-
(EGF- ) like domain that speciﬁcally activates ErbB receptor
tyrosine kinases [9, 10]. Among the ErbB receptors, ErbB4
is the major mediator of NRG1 function in the brain [11,
12]. In the central nervous system, NRG1-ErbB4 signaling
regulates neural and glial development [13], axon myelina-
tion and ensheathment [14–17], synaptic plasticity [11, 18],
expression and activation of neurotransmitter receptors [2,
18], neurotrophic coupling, and neuroprotection following
neurological disorders [11].
Importantly, dysregulation and dysfunction of NRG1
andErbB4maybeassociatedwithsometypesofneurological
disorders [19]. Clinical evidence has revealed altered NRG1
and its receptor ErB4 expressions in postmortem brains
of schizophrenia patients [5, 20, 21]. Since the above
tested brain samples of all patients received antipsychotic
treatment before death, the association of the altered NRG1
and ErbB4 expressions with schizophrenia pathology or
antipsychotic drug eﬀects remains unknown. Therefore, it
is fundamentally and clinically signiﬁcant to investigate the
role and mechanism of NRG1 and ErB4 in animal models2 Journal of Biomedicine and Biotechnology
of schizophrenia. By doing so, for the ﬁrst step, in this study
we aimed to determine whether there is altered expression of
NRG1 and ErbB4 in an animal model of schizophrenia.
Among a number of schizophrenia animal models, a
very commonly used rat model is induced by chronic
dizocilpine maleate (MK-801, a noncompetitive NMDA
receptor antagonist) administration, which was selected in
this study [22, 23]. This model was based on the key
pathological mechanism of NMDA glutamatergic hypofunc-
tion in schizophrenia [24]. It has been well documented
that repeated administration of NMDA receptor antago-
nists could induce schizophrenia-like behavioral deﬁcits in
normal rats [25, 26]. In this animal model, we examined
expressions of NRG1β and ErbB4 proteins in the prefrontal
cortex and hippocampus, because the two brain regions are
closely related to the pathophysiology of schizophrenia [27–
29].
2.MaterialsandMethods
2.1. Animals. Adult male Wistar rats (Vital River, Beijing,
China) weighing 185–225g were group-housed under a 12-
hour light/dark cycle with ad libitum access to both food and
water. All procedures were performed in accordance with the
National Institute of Health’s Guide for the Use and Care
of Laboratory Animals and were approved by the Peking
University Committee on Animal Care and Use.
2.2. Drug Treatment. MK-801 (St. Louis, MO, USA) was
dissolved with normal saline. After a 1-week acclimatization,
the rats were randomly divided into two groups, and each
rat received intraperitoneal injection of either MK-801
(0.5mg/kg, n = 10) or normal saline (vehicle, n = 10) for
4 weeks. The dosage of the MK-801 used in this study was
based on other previous studies [30]. All rats received single,
daily injection between 09:00 and 11:00 am.
2.3. Immunohistochemistry. The rats (n = 5p e rg r o u p )w e r e
deeply anaesthetized with chloral hydrate (300mg/kg) and
transcardially perfused with 250mL cool saline solution
followed by 300mL of 4% paraformaldehyde in 0.1M phos-
phatebuﬀeredsaline(PBS,pH7.4).Brainswereimmediately
removed, postﬁxed in the same ﬁxative overnight, and
cryoprotected in 30% sucrose at 4◦C for 5d. After quenching
by immersing them in cold N-hexane on dry ice, the brains
were stored at −80
◦C until analyzed.
Serial coronal sections of 20μm thickness at various lev-
els (100μm interval) through the prefrontal cortex (bregma
3.72–2.52) and hippocampus (bregma −2.76 to −3.96)
[31] were cut on a cryostat (Leica, Wetzlar, Germany)
and slide-mounted. After blocking in 10% normal goat
serum in 0.1M PBS containing 0.3% Triton X-100 for 1
hour at room temperature (RT), sections were incubated
with NRG1β- (sc-347) or ErbB4- (sc-283, all from Santa
Cruz Biotechnology Inc., Santa Cruz, CA, USA) speciﬁc
antibodies diluted 1 : 100 in 0.1M PBS overnight at 4◦C.
The next morning, sections were incubated with primary
antibodies for an additional 1 hour at RT, followed by
incubation with biotinylated secondary antibodies (Santa
Cruz Biotechnology Inc.) for 3 hours at RT, and then
incubated with avidin-biotin-horseradish peroxidase (Santa
Cruz Biotechnology Inc.) for 3 hours at RT. Finally, the
sections were developed with a solution of 50% 3,3 -
diaminobenzidine (DAB) and 3% hydrogen peroxide in
0.1M PBS, dehydrated, and coverslipped.
Four sections (20μm thickness, 100μm interval) from
the prefrontal cortex and hippocampus were obtained
and immunoreactivity was determined and quantitated as
previously described [32]. Brieﬂy, immunoreactive staining
was observed and photographed at ×40 magniﬁcation using
an Olympus BX51 microscope ﬁtted with a CoolSNAP
MP5 CCD camera (Roper Scientiﬁc, Tucson, AZ, USA).
I m a g e sw e r ec o n v e r t e dt og r e ys c a l ea n da n a l y z e dw i t h
Image Pro-Plus software (Media Cybernetics, Silver Spring,
MD, USA). For calculating immunoreactivity of prefrontal
c o r t e x ,a1× 1mm 2 cursor was placed on the prelimbic
cortex (PrL) or the cingulate cortex area 1 (Cg1) plus
secondary motor cortex (M2) [31]. Constant background
intensity across diﬀerent sections from each animal was
set so that positivelabeled cells were selected only if they
reached a deﬁned threshold above background, then the
integrated optical density (IOD = immunoreactive area ×
average optical density) values of PrL and Cg1 plus M2 were
measured and designated as optical density (OD). Optical
density value of hippocampal subregions and background
were measured by placing several adjacent circular cursors
with a diameter of 100 μm along the pyramidal cell layer
of CA1 (8 cursors) and CA3 (12 cursors), the granule cell
layerofDG(8cursors),andcorpuscallosum(CC,8cursors).
Optical density values of corpus callosum were designated as
background. The diﬀerences of value between the target and
backgroundwerecalculatedanddesignatedasOD.Allresults
were normalized by taking the value of the vehicle group as
100%.
2.4. Western Blot. After sacriﬁcing animals, the brains were
rapidlyremovedanddissectedtoobtaintheprefrontalcortex
and hippocampus [33]. Tissue from individual rats was
immediately homogenized on ice in ice-cold lysis buﬀer
(137mM NaCl, 20mM Tris–HCl (pH 8.0), 1% NP-40,
10% glycerol, 1mM PMSF, 10mg/mL aprotinin, 1mg/mL
leupeptin, and 0.5mM sodium vanadate), sonicated, and
centrifuged. The supernatants were stored at −80
◦C until
assayed.
Samples containing 20μg of protein were resolved by
7.5% (for detection of ErbB4 receptor) or 10% (for NRG1β
isoforms) SDS–PAGE gels. Immunoblotting was conducted
withNRG1β- (sc-347, 1 : 1000) or ErbB4- (sc-283, 1 : 1000)
speciﬁc antibodies (all from Santa Cruz Biotechnology
Inc.). We stripped and reprobed bolts with rabbit anti-
actin polyclonal antibody (Santa Cruz Biotechnology Inc.).
The immunoreactive signals of NRG1β and ErbB4 were
quantiﬁed by densitometry and the values were corrected
based on their corresponding actin levels. All results were
normalized by taking the value of the vehicle group as
100%.Journal of Biomedicine and Biotechnology 3
Table 1: Immunoreactivity of NRG1β and ErbB4 in the rat pre-
frontal cortex and hippocampal subregions.
Vehicle MK-801
PFC NRG1β Cg1 and M2 100 ±6.12 101.84 ±6.69
PrL 100 ±4.79 108.75 ±5.09
ErbB4 Cg1 and M2 100 ±7.96 125.33 ±7.45
PrL 100 ±6.08 135.09 ±8.03
∗
HC NRG1β CA1 100 ±10.79 204.08 ±10.87
∗
CA3 100 ±7.69 142.92 ±6.39
∗
DG 100 ±10.29 167.18 ± 11.02
∗
ErbB4 CA1 100.00 ±6.28 140.23 ±8.66
∗
CA3 100.00 ±4.87 106.27 ±5.94
DG 100.00 ±7.48 106.32 ±7.04
PFC: prefrontal cortex; HC: hippocampus; Cg1: cingulate cortex area 1; M2:
secondary motor cortex; PrL: prelimbic cortex; DG: dentate gyrus.
∗P <. 05 compared to vehicle group.
2.5. Antibody Speciﬁcity. The speciﬁcity of antibodies was
examined by Western blot as previously described [32].
The signal of the 65kDa NRG1β isoform was reduced and
labeling of the other NRG1 β isoforms and ErbB4 isoforms
waseliminatedbypreabsorptionwithcorrespondingantigen
peptides(SantaCruzBiotechnologyInc.).Antibodiesagainst
actin generated one main band.
2.6. Statistical Analysis. All data were expressed as the
means ± S.E.M. Statistical diﬀerences between groups were
determined by independent samples t-test. Diﬀerences of
P<. 05 were considered to be signiﬁcant.
3. Results
3.1. Changes of NRG1β and ErbB4 Protein Expressions in
the Prefrontal Cortex. Protein samples extracted from rat
prefrontalcortexwereanalyzedbyWesternblot.Quantitative
data showed that expressions of all ﬁve NRG1β isoforms
were signiﬁcantly elevated with relative levels (% of vehicle
treated controls) of 220 ± 5 for 35kDa isoform, 245 ± 22
for 65kDa isoform, 255 ± 23 for 80kDa isoform, 266 ±
10 for 85kDa isoform, and 224 ± 18 for 95 kDa isoform,
respectively, while all three isoforms of ErbB4 were also
signiﬁcantly upregulated with relative levels (% of vehicle
treated controls) of 190 ± 26 for 60kDa isoform, 164 ±
5 for 120kDa isoform, and 199 ± 12 for 185kDa isoform,
respectively (Figures 1(a)–1(d)).
Immunohistochemistry was applied to localize and
quantitate NRG1β and ErbB4 immunoreactivity in diﬀerent
subregions of prefrontal cortex (Figures 1(e)–1(h) and
Table 1).Quantiﬁcationofimmunoreactiveintensityshowed
slightincreasesofNRG1β expressioninthetwocortexsubre-
gions of prelimbic cortex (PrL) and the cingulate cortex area
1 plus secondary motor cortex (Cg1 and M2), but did not
reach statistic signiﬁcance. However, the immunoreactivity
of ErbB4 was signiﬁcantly increased in the PrL region, while
no signiﬁcant diﬀerence was observed in Cg1 and M2 region.
FromtheDAB-stainedmorphologyofimmunopositive cells,
it is noticed that they are mainly neuron-like cells [32].
3.2. Changes of NRG1β and ErbB4 Protein Expressions in the
Hippocampus. Western blot analysis revealed that expres-
sions of three NRG1β isoforms were signiﬁcantly elevated
with relative levels (% of vehicle treated controls) of 169
± 7 for 35kDa isoform, 159 ± 17 for 65kDa isoform, and
134 ± 12 for 95kDa isoform, respectively; while all three
isoforms of ErbB4 were also signiﬁcantly upregulated with
relative levels (% of vehicle treated controls) of 330 ± 28 for
60 kDa isoform, 221 ± 15 for 120kDa isoform, and 235 ± 26
for 185kDa isoform, respectively (Figures 2(a)–2(d)).
Consistent with Western blot results, immunostaining
analysis revealed signiﬁcant increases of NRG1β immunore-
activity in the pyramidal cell layer of CA1 and CA3 and in
the granule cell layer of the dentate gyrus (Figures 2(e)–
2(j) and Table 1). Similar to the results for NRG1β,M K -
801 increased expression of ErbB4 receptor in the CA1
subregion, while there were no signiﬁcant diﬀerences that
canbedetectedinCA3andthedentategyrus.FromtheDAB-
stained morphology of immunopositive cells, it ia noticed
that they are mainly neuron-like cells [32].
4. Discussion
Our major ﬁndings from this study were that in this
schizophrenia animal model induced by chronic MK-801
administration, Western blot results showed signiﬁcantly
increased protein levels of NRG1 in the rat prefrontal cortex,
while immunohistochemistry analysis observed the increase
of NRG1 immunoreactivity in the PrL and the Cg1 and
M2 regions, but it did not reach statistic signiﬁcance. This
discrepancy results between Western blot and immuohisto-
chemistry may be due to the diﬀerent sensitivity of these two
assessmentsandsmallsamplesize.Additionally,inthisstudy,
we found that protein level of ErbB4 is upregulated in the rat
prefrontal cortex by Western blot, while the immunoreactiv-
ity of ErbB4 only increased in the PrL region. Furthermore,
protein levels of both NRG1 and ErbB4 were increased
in rat hippocampus, but the increased immunoreactivities
of the two proteins were located in diﬀerent subregions.
Signiﬁcantly increased NRG1 immuoreactivity can be seen
in the pyramidal cell layer of CA1 and CA3 and in the
granule cell layer of the dentate gyrus, while ErbB4 was only
signiﬁcantly increased in CA1 subregion. There might be
important role and mechanisms beyond the distinguishable
expressionpatternsofNRG1andErbB4inthisschizophrenia
model which need further investigations.
Our ﬁndings are consistent with the clinical obser-
vations of dysregulated expression of NRG1 and ErbB4
in postmortem brain of schizophrenia patients [20, 21].
Interestingly, our previous study found that changes of
NRG1 and ErbB4 protein levels can be induced by chronic
administration of antipsychotic drugs in normal rat pre-
frontal cortex and hippocampus [32], indicating that reg-
ulations of NRG1 and ErbB4 proteins may be associated4 Journal of Biomedicine and Biotechnology
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Figure 1: Expression of NRG1β and ErbB4 proteins in the rat prefrontal cortex. (a) Representative Western blots of NRG1β protein
isoforms. (b) Quantitative analysis of NRG1β immunoblots. (c) Representative Western blots of ErbB4 proteins isoforms. (d) Quantitative
analysis of ErbB4 immunoblots. The data were normalized by taking the value of vehicle group as 100% and expressed as means ±
S.E.M. (n = 5).
∗P <. 05. (e) Representative section of ErbB4 immunohistochemistry in the PrL region of prefrontal cortex from vehicle
group. (f) Representative section of ErbB4 immunohistochemistry in the PrL region of prefrontal cortex from MK-801-treated group. (g)
RepresentativesectionofErbB4immunohistochemistryintheCg1andM2regionofprefrontalcortexfromvehiclegroup.(h)Representative
sectionofErbB4immunohistochemistryintheCg1andM2regionofprefrontalcortexfromMK-801-treatedgroup.ArrowsindicateErbB4-
expressing neurons in the prefrontal cortex. Scale bar for (e)–(h): 50μm.Journal of Biomedicine and Biotechnology 5
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Figure2:ExpressionofNRG1βandErbB4proteinsintherathippocampus.(a)RepresentativeWesternblotsofNRG1βproteinisoforms.(b)
QuantitativeanalysisofNRG1βimmunoblots.(c)RepresentativeWesternblotsofErbB4proteinisoforms.(d)QuantitativeanalysisofErbB4
immunoblots. The data were normalized by taking the value of vehicle group as 100% and expressed as means ± S.E.M. (n = 5).
∗P <. 05.
(e) Representative section of NRG1β immunohistochemistry in the hippocampal CA1 region from vehicle group. (f) Representative section
of NRG1β immunohistochemistry in the hippocampal CA1 region from MK-801-treated group. (g) Representative section of NRG1β
immunohistochemistry in the hippocampal CA3 region from vehicle group. (h) Representative section of NRG1β immunohistochemistry in
the hippocampal CA3 region from MK-801-treated group. (i) Representative section of NRG1β immunohistochemistry in the hippocampal
DG region from vehicle group. (j) Representative section of NRG1β immunohistochemistry in the hippocampal DG region from MK-801-
treated group. Arrows indicate NRG1-expressing neurons in the hippocampus. Scale bar for (e)–(j): 50μm.6 Journal of Biomedicine and Biotechnology
with pathophysiological cascades and therapeutic outcomes
of schizophrenia.
Although the roles and mechanisms of the increased
NRG1 and ErbB4 in this rat schizophrenia model and
correlation to the schizophrenia pathophysiology are incom-
pletely understood from this study, the potential roles
and mechanisms might be speculated. Our data showed
that repeated blockade of NMDA receptor increased the
expression of NRG1 and ErbB4, suggesting that changes
of both NRG1 and ErbB4 expressions are associated with
NMDAreceptorfunctioninthisratmodelforschizophrenia.
Perhaps this is due to the fact that ErbB4 colocalizes with
NMDA receptors at postsynaptic sites through interaction
with PDZ domain-containing proteins, presuming that there
is cross-talk between NMDA receptor and NRG1-ErbB4
signaling [20, 34, 35].
We are aware that there are several limitations in
this short study. We did not study the time course of
NRG1 and ErbB4 expression and correlation to the late
behavioral deﬁcits, which need to be performed in the
future. Since we only tested this rat schizophrenia animal
model, we need to know whether increased expression of
NRG1 and ErbB4 in other schizophrenia animal models
is a common pathological phenomenon of schizophrenia.
Except the protein expression changes, we also need to know
the function changes of NRG1-ErbB4 signaling, in terms
of better understanding their roles and mechanisms. The
cellular sources and subcellular distributions of both NRG1
and ErbB4 need to be carefully deﬁned with double staining
techniques. Lastly, genetic alteration and pharmacological
approaches for manipulating NRG1 and ErbB4 expressions
can be applied to further investigate their pathological
importance and therapeutic potentials in schizophrenia.
5. Conclusion
Insummary,ourpresentstudyindicatesthatproteinlevelsof
NRG1β andErbB4intheprefrontalcortexandhippocampus
are increased in this rat model of schizophrenia induced by
repeatedMK-801administration.Theseﬁndingssuggestthat
altered expressions of NRG1 and ErbB4 might attribute to
the schizophrenia. Further study of the role and mechanism
of NRG1 and ErbB4 may lead to better understanding of the
pathophysiology of schizophrenia.
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